Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 12/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.81 |
| ▸ | NPC1 | O15118 | 8/20 | 0.81 |
| ▸ | PKM | P14618 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | RAB9A | P51151 | 8/20 | 0.76 |
| ▸ | CASP3 | P42574 | 1/20 | 0.73 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.73 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.73 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.73 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | VCP | P55072 | 1/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7540052 | 0.99 | MAPK1 (0.84) | MAPK1MEN1KMT2ANPC1PKM | |
| SCHEMBL28319654 | 0.92 | MEN1 (0.74) | MAPK1MEN1KMT2ANPC1PKM | |
| SCHEMBL1889546 | 0.91 | MEN1 (0.76) | MAPK1MEN1KMT2ANPC1PKM | |
| SCHEMBL22560267 | 0.90 | MAPK1 (1.00) | MAPK1MEN1KMT2ANPC1PKM | |
| SCHEMBL12157931 | 0.90 | MEN1 (1.00) | MAPK1MEN1KMT2ANPC1PKM | |
| Bromide SCHEMBL7674933 | 0.89 | MAPK1 (0.82) | MAPK1MEN1KMT2ANPC1PKM | |
| SCHEMBL12639823 | 0.89 | MAPK1 (0.86) | MAPK1MEN1KMT2ANPC1PKM | |
| SCHEMBL7557437 | 0.87 | MAPK1 (0.84) | MAPK1MEN1KMT2ANPC1PKM | |
| SCHEMBL7679868 | 0.87 | MAPK1 (0.82) | MAPK1MEN1KMT2ANPC1PKM | |
| SCHEMBL23539303 | 0.86 | MEN1 (0.81) | MAPK1MEN1KMT2ANPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974795-B2 | Anticancer agent composition | CARNA BIOSCIENCES, INC. (JP) | 2018-05-22 | — | — | US | claimed |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CARNA BIOSCIENCES, INC. (JP) | 2017-03-09 | — | — | US | claimed |
| EP-3100742-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences Inc. (JP) | 2016-12-07 | — | — | EP | claimed |
| EP-3100742-B1 | ANTICANCER AGENT COMPOSITION COMPRISING A CDC7 INHIBITOR AND A WEE1 INHIBITOR | CARNA BIOSCIENCES INC (JP) | 2020-05-20 | — | — | EP | disclosed |
| US-9974795-B2 | Anticancer agent composition | CARNA BIOSCIENCES, INC. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CARNA BIOSCIENCES, INC. (JP) | 2017-03-09 | — | — | US | disclosed |
| EP-3100742-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences Inc. (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-6391894-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CDC7, CDC16, MCM7 | MAPK1 1123/4885MEN1 673/4885KMT2A 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.